Allelic Frequency of the PAI‐1 4G/5G Promoter Polymorphism in Patients with Type 2 Diabetes Mellitus and Lack of Association with PAI‐1 Plasma Levels

References

• Francis R B, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein D I. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776–780
   PubMed Web of Science ®Google Scholar
• Meade T W, Ruddock B, Stirling Y, Chakrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long‐term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076–1079
   PubMed Web of Science ®Google Scholar
• Thogersen A M, Jansson J H, Boman K, Nilsson T K, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor‐1 and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1988; 98: 2241–2247
   Google Scholar
• Held C, Hjemdahl P, Rehnqvist N, Wallen N H, Bjorkander I, Eriksson S V, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the angina prognosis study in Stockholm. Circulation 1997; 95: 2380–2386
   PubMed Web of Science ®Google Scholar
• Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Sawdey M S, Keeton M R, Bordin G M, Bernstein E F, Dilley R B, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89: 6998–7002
   PubMed Web of Science ®Google Scholar
• Dawson S J, Wiman B, Hamsten A, Green F, Humphries S, Henney A M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor‐1 (PAI‐1) gene respond differently to interleukin‐1 in HepG2 cells. J Biol Chem 1993; 268: 10739–10745
   PubMed Web of Science ®Google Scholar
• Eriksson P, Kallin B, van't Hooft F M, Bavenholm P, Hamsten A. Allele‐specific increase in basal transcription of the plasminogen‐activator inhibitor‐1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851–1855
   PubMed Web of Science ®Google Scholar
• Mansfield M W, Stickland M H, Grant P J. Plasminogen activator inhibitor‐1 (PAI‐1) promoter polymorphism and coronary artery disease in non‐insulin‐dependent diabetes. Thromb Haemost 1995; 74: 1032–1034
   PubMed Web of Science ®Google Scholar
• Mansfield M W, Stickland M H, Grant P J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor‐1 in Caucasian patients with non‐insulin‐dependent diabetes mellitus. Thromb Haemost 1995; 74: 842–847
   PubMed Web of Science ®Google Scholar
• Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G. Genotype frequency of plasminogen activator inhibitor‐1 (PAI‐1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI‐1 levels. Int J Hematol 1999; 69: 43–47
   PubMed Web of Science ®Google Scholar
• Hoffstedt J, Andersson I L, Persson L, Isaksson B, Arner P. The common − 675 4G/5G polymorphism in the plasminogen activator inhibitor‐1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584–587
   PubMed Web of Science ®Google Scholar
• Leander K, Wiman B, Hallqvist J, Sten‐Linder M, De Faire U. PAI‐1 level and the PAI‐1 4G/5G polymorphism in relation to risk of non‐fatal myocardial infarction. Thromb Haemost 2003; 89: 1064–1071
   PubMed Web of Science ®Google Scholar
• Yamada Y, Izawa H, Ichihara S, Takatsa F, Ishihara H, Hirayama H. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916–1923
   PubMed Web of Science ®Google Scholar
• Nagi D K, Mc Cormack L J, Mohamed‐Ali V, Yudkin J S, Knowler W C, Grant P J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI‐1 gene, and PAI‐1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997; 20: 1304–1309
   PubMed Web of Science ®Google Scholar
• Globocnik‐Petrovic M, Halina M, Peterlin B, Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin‐converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Opthalmologica 2003; 217: 219–224
   PubMed Web of Science ®Google Scholar
• Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T. Enhanced expression of PAI‐1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800–803
   PubMed Web of Science ®Google Scholar
• Samad F, Yamamoto K, Loskutoff D. Distribution and regulation of plasminogen activator inhibitor‐1 in murine adipose tissue in vivo: induction by tumor necrosis factor‐α and lipopolysaccharide. J Clin Investig 1996; 97: 37–46
   PubMed Web of Science ®Google Scholar
• Samad F, Schneiderman J, Loskutoff D. Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice. Ann N Y Acad Sci 1997; 811: 350–358
   PubMed Web of Science ®Google Scholar
• Alessi M C, Morange P, Juhan‐Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000; 32: 504–508
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I, Alessi M C, Morange P E. Hypofibrinolysis and increased PAI‐1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32: 78–84
   PubMed Web of Science ®Google Scholar
• Halleux C M, Declerck P J, Tran S L, Detry R, Brichard S M. Hormonal control of plasminogen activator inhibitor‐1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097–4105
   PubMed Web of Science ®Google Scholar
• Alessi M C, Peiretti F, Morange P, Henry M, Nalbone G, Juhan‐Vague I. Production of plasminogen activator inhibitor‐1 by human adipose tissue. Diabetes 1997; 46: 860–867
   PubMed Web of Science ®Google Scholar
• Lundgren C H, Brown S L, Nordt T K, Sobel B E, Fujii S. Elaboration of type‐1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106–110
   PubMed Web of Science ®Google Scholar
• Kohner E M, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe. Eur J Ophthal 1991; 1: 45–54
   PubMedGoogle Scholar
• Gregor P D, Sawadogo M, Roeder R G. The adenovirus major late transcription factor USF is a member of the helix‐loop‐helix group of regulatory proteins and binds to DNA as a dimer. Genes Dev 1990; 4: 1730–1740
   PubMed Web of Science ®Google Scholar
• Shieh B H, Sparkes R S, Gaynor R B, Lusis A J. Localization of the gene encoding upstream stimulatory factor (USF) to human chromosome 1q22–q23. Genomics 1993; 16: 266–268
   PubMed Web of Science ®Google Scholar
• Groenen P MA, Garcia E, Debeer P, Devriendt K, Fryns J P, Van de Ven W JM. Structure, sequence, and chromosome 19 localization of human USF‐2 and its rearrangement in a patient with multicystic renal dysplasia. Genomics 1996; 38: 141–148
   PubMed Web of Science ®Google Scholar
• Henrion A A, Martinez A, Mattei M G, Kahn A, Raymondjean M. Structure, sequence, and chromosomal localization of the gene for USF‐2 transcription factor in mouse. Genomics 1995; 25: 36–43
   PubMed Web of Science ®Google Scholar
• Samoylenko A, Roth U, Jungermann K, Kietzmann T. The upstream stimulatory factor‐2a inhibits plasminogen activator inhibitor‐1 gene expression by binding to a promoter element adjacent to the hypoxia‐inducible factor‐1 binding site. Blood 2001; 97: 2657–2666
   PubMed Web of Science ®Google Scholar
• Providence K M, White L A, Tang J, Gonclaves J, Staiano‐Coico L, Higgins P J. Epithelial monolayer wounding stimulates binding of USF‐1 to an E‐box motif in the plasminogen activator type 1 gene. J Cell Sci 2002; 115: 3767–3777
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R, Jr, Rich S S, Jeny N S, Tracy R P, Haffner S M. Promoter (4G/5G) plasminogen activator inhibitor‐1 genotype and plasminogen activator inhibitor‐1 levels in Blacks, Hispanics, and non‐Hispanics Whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107: 2422–2427
   PubMed Web of Science ®Google Scholar
• Westendorp R GJ, Hottenga J J, Slagboom P E. Variation in plasminogen‐activator–inhibitor‐1 gene and risk of meningococcal septic shock. Lancet 1999; 354: 561–563
   PubMed Web of Science ®Google Scholar
• Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54–59
   PubMed Web of Science ®Google Scholar
• Meade T W, Ruddock B, Stirling Y, Chakrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long‐term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076–1079
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Aillaud M F, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI‐1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction—the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80: 749–756
   PubMed Web of Science ®Google Scholar
• Mansfield M W, Stickland M H, Carter A M, Grant P J. Polymorphisms of the plasminogen activator inhibitor‐1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731–736
   PubMed Web of Science ®Google Scholar